Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iroko Pharmaceuticals has acquired all non-US commercial rights to heart drug Aggrastat from Merck & Co.
Subscribe to our email newsletter
Aggrastat is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and who are undergoing percutaneous transluminal coronary angioplasty. Outside of the US market, Aggrastat in combination with heparin is indicated for patients with unstable angina or non-Q wave myocardial infarction.
John Vavricka, president and CEO of Iroko, said: “This acquisition plays to our strengths in focused sales and marketing efforts and building close working relationships with key opinion leaders.”